Login / Signup

Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy.

Yehoda M MarteiMohan NarasimhamurthyDipho I SetlhakoGezahen AyaneTlotlo B RalefalaSebathu ChiyapoRobert GrossLawrence N ShulmanSurbhi GroverAngela M DeMichele
Published in: JCO global oncology (2022)
Patients who are HIV-positive and have breast cancer in Botswana have lower pCR rates and also receive lower dose intensity therapy, which may contribute to worse OS. Patients who are HIV-positive on ZDV-containing regimens received even lower dose intensity of NACT. Administering optimal dose intensity in patients who are HIV-positive remains a challenge, and targeted interventions that address modifiable risk factors are needed to improve therapy delivery and outcomes.
Keyphrases